Supernus undervalued after Indivior merger, says Bank of America
Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.
How this was made
The 30-second read
Why it matters
The new coverage could trigger buying pressure on SUPN and modest interest in INDV as investors reassess the combined company's growth prospects.
Market read
Analyst upgrade on a post‑merger pharma company provides a clear trade idea for SUPN and secondary interest for INDV.
What to watch
Potential regulatory scrutiny of opioid‑related products and execution risk of cost synergies.
Background
Bank of America provides its first coverage of Supernus after the Indivior merger, assigning a buy rating and a $47 price target based on projected earnings expansion.
Ticker impact
Bank of America initiates coverage with a buy rating and $47 price target for Supernus post‑Indivior merger.
likely upward pressure as investors price in the new valuation multiple.
The coverage highlights a discount to peers and a projected revenue/EBITDA boost, prompting buying interest.
The merger with Indivior is central to the analyst's valuation thesis for Supernus.
potential modest upside as the market assesses the merged entity's earnings profile.
Indivior's addiction portfolio reduces patent‑expiry risk, supporting a higher multiple for the combined business.
Market effects
Pharma sector may see re‑rating of other opioid‑treatment and neurology players.
U.S. biotech and specialty pharma stocks could experience spill‑over buying.
Limited to U.S. and global specialty pharma investors.
Counterpoint
If integration risks materialize, the projected growth may be overstated, limiting upside.
Key entities
- companySupernus Pharmaceuticals
U.S. specialty pharma firm, ticker SUPN.
- companyIndivior
U.S. addiction‑treatment company, ticker INDV.
- analystBank of America
Initiated coverage with a buy rating and price target.
